Summary
Mundipharma International Limited (Mundipharma) researches and develops products for the treatment pain management, respiratory, cancer and inflammatory conditions. The company commercializes and launches products within Europe and rest of the world. Mundipharma offers its products through its network of subsidiaries, independent associated companies, partners and joint ventures. The company’s network includes Napp Pharmaceuticals, Norpharma and the Mundipharma independent associated companies. The company provides its services to patients, healthcare professionals and health systems worldwide. It has operations in Australia, Japan, New Zealand, Russia, Singapore, Philippines, South Africa, South Korea, Canada, China and USA. Mundipharma is headquartered in Cambridge, the UK.
Mundipharma International Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Mundipharma International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 14
Purdue Pharma Acquires Rights to VM-902A from VM Pharma 15
Venture Financing 16
Kolltan Pharma Raises US$60 Million In Series D Financing 16
Partnerships 18
Allos Therapeutics Enters Into Collaboration And Licensing Agreement With Mundipharma International For FOLOTYN 18
Mundipharma Enters into Distribution Agreement with Shionogi 20
Purdue Pharma to Form Joint Venture with AnaBios 21
Eisai Enters into Agreement with Purdue Pharma 22
Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 23
Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 25
ElMindA Enters Into Agreement With Purdue Pharma To Develop New Pain Drugs 27
Mundipharma International Enters Into Co-Development Agreement With Northlake International For NL-101 28
Infinity Pharma Terminates Co-Development Agreement With Mundipharma And Purdue Pharma 30
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 32
Purdue Pharma Enters Into Co-Marketing Agreement With Transcept Pharma 34
Infinity Pharma Extends Co-Development Agreement With Mundipharma 36
Infinity Pharma Extends Its Collaboration Agreement With Mundipharma International 38
Horizon Pharma Enters Into Distribution Agreement With Mundipharma International Corporation For LODOTRA 40
Mundipharma International And Purdue Pharma Exercises Rights To Infinity's FAAH Program 42
Licensing Agreements 44
Mundipharma Enters into Licensing Agreement with Specialized Therapeutics 44
Mundipharma International Enters into Licensing Agreement with Helsinn 45
Mundipharma Enters into Licensing Agreement with SkyePharma for Flutiform in Mexico, Central and South America 46
SkyePharma Enters into Option Agreement with Mundipharma 48
Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 49
Mundipharma Enters into Licensing Agreement with Medical Developments for Penthrox 51
Mundipharma Enters into Licensing Agreement with Helsinn 52
Helsinn Enters into Licensing Agreement with Mundipharma for Anamorelin 53
Helsinn Enters into Licensing Agreement with Mundipharma for NEPA 54
Mundipharma Plans to Extend Licensing Agreement with Genewel for Medifoam 55
Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 56
Mundipharma Enters into Licensing Agreement with Genewel for Medifoam 58
Mundipharma Enters Into Licensing Agreement With Grunenthal 59
Helsinn Enters Into Licensing Agreement With Mundipharma For Netupitant-Palonosetron Fixed Dose Combination 60
Mundipharma Enters Into Licensing Agreement With Shionogi 62
Allos Therapeutics Amends Licensing Agreement With Mundipharma International For Folotyn 63
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 65
Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 66
Helsinn Healthcare Enters Into Licensing Agreement With MundiPharma 67
Mundipharma International Ltd - Key Competitors 69
Key Employees 70
Locations And Subsidiaries 71
Head Office 71
Other Locations & Subsidiaries 71
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75
List of Tables
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Key Facts 1
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Mundipharma International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Mundipharma International Ltd, Deals By Therapy Area, 2010 to YTD 2016 10
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 14
Purdue Pharma Acquires Rights to VM-902A from VM Pharma 15
Kolltan Pharma Raises US$60 Million In Series D Financing 16
Allos Therapeutics Enters Into Collaboration And Licensing Agreement With Mundipharma International For FOLOTYN 18
Mundipharma Enters into Distribution Agreement with Shionogi 20
Purdue Pharma to Form Joint Venture with AnaBios 21
Eisai Enters into Agreement with Purdue Pharma 22
Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 23
Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 25
ElMindA Enters Into Agreement With Purdue Pharma To Develop New Pain Drugs 27
Mundipharma International Enters Into Co-Development Agreement With Northlake International For NL-101 28
Infinity Pharma Terminates Co-Development Agreement With Mundipharma And Purdue Pharma 30
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 32
Purdue Pharma Enters Into Co-Marketing Agreement With Transcept Pharma 34
Infinity Pharma Extends Co-Development Agreement With Mundipharma 36
Infinity Pharma Extends Its Collaboration Agreement With Mundipharma International 38
Horizon Pharma Enters Into Distribution Agreement With Mundipharma International Corporation For LODOTRA 40
Mundipharma International And Purdue Pharma Exercises Rights To Infinity's FAAH Program 42
Mundipharma Enters into Licensing Agreement with Specialized Therapeutics 44
Mundipharma International Enters into Licensing Agreement with Helsinn 45
Mundipharma Enters into Licensing Agreement with SkyePharma for Flutiform in Mexico, Central and South America 46
SkyePharma Enters into Option Agreement with Mundipharma 48
Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 49
Mundipharma Enters into Licensing Agreement with Medical Developments for Penthrox 51
Mundipharma Enters into Licensing Agreement with Helsinn 52
Helsinn Enters into Licensing Agreement with Mundipharma for Anamorelin 53
Helsinn Enters into Licensing Agreement with Mundipharma for NEPA 54
Mundipharma Plans to Extend Licensing Agreement with Genewel for Medifoam 55
Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 56
Mundipharma Enters into Licensing Agreement with Genewel for Medifoam 58
Mundipharma Enters Into Licensing Agreement With Grunenthal 59
Helsinn Enters Into Licensing Agreement With Mundipharma For Netupitant-Palonosetron Fixed Dose Combination 60
Mundipharma Enters Into Licensing Agreement With Shionogi 62
Allos Therapeutics Amends Licensing Agreement With Mundipharma International For Folotyn 63
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 65
Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 66
Helsinn Healthcare Enters Into Licensing Agreement With MundiPharma 67
Mundipharma International Ltd, Key Competitors 69
Mundipharma International Ltd, Key Employees 70
Mundipharma International Ltd, Subsidiaries 71
List of Figures
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 8
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
